Osborne Partners Capital Management LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 25.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 43,966 shares of the medical research company’s stock after buying an additional 8,793 shares during the period. Thermo Fisher Scientific makes up about 1.1% of Osborne Partners Capital Management LLC’s investment portfolio, making the stock its 24th largest holding. Osborne Partners Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $21,610,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in TMO. High Note Wealth LLC raised its holdings in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $28,000. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth $28,000. Beacon Financial Strategies CORP bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $29,000. Finally, Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $29,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Thermo Fisher Scientific Price Performance
NYSE TMO opened at $522.38 on Friday. The company has a 50-day moving average price of $473.17 and a 200-day moving average price of $518.15. Thermo Fisher Scientific Inc. has a 52 week low of $403.36 and a 52 week high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $194.13 billion, a P/E ratio of 28.72, a PEG ratio of 2.32 and a beta of 0.87.
Thermo Fisher Scientific Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 10.34%.
Insider Activity at Thermo Fisher Scientific
In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
TMO has been the subject of a number of recent analyst reports. Weiss Ratings lowered Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 target price on the stock. Finally, Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $605.09.
View Our Latest Research Report on TMO
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Stories
- Five stocks we like better than Thermo Fisher Scientific
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
